The Norwegian Study of Nervous System Manifestations and Sequelae After COVID-19

Covid19 Clinical Trial

— NeuroCovid  

Official title:

The Norwegian Study of Nervous System Manifestations and Sequelae After COVID-19

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04576351
• Other study ID #: 152727
• Status: Recruiting
• Start date: September 1, 2020
• Est. completion date: December 31, 2023

Study information

• Verified date: March 2021
• Source: Oslo University Hospital
• Contact: Anne Hege Aamodt, MD, PhD
• Phone: 95867270
• Email: a.h.aamodt[@]medisin.uio.no
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Neurologic, neuropsychological and neuropsychiatric symptoms, signs and diagnoses are increasingly being reported in COVID-19 patients. However, the extent and implications of such "NeuroCOVID" involvement, as well as blood and MRI biomarkers for neurological and psychiatric COVID-19-affection and treatments, warrants further studies. The investigator will perform a national study with clinical and biomarker assessments of NeuroCOVID in approximately 150 Norwegian patients, recruited from ongoing COVID-studies in Norway as well as from neurological departments in Norway. The investigator will define the burden of neurological, psychological and psychiatric complications of COVID-19 disease and identify clinical characteristics and biomarkers for both short- and long-term neurological treatment and rehabilitation. Blood samples for biomarker analyses, brain MRI, clinical neurological, neurophysiological and neuropsychological assessments will be performed at 6 and 12 moths after acute disease,

Description:

Corona virus (CoV) may have deleterious effects on the nervous system. As the number of individuals infected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is increasing, more and more neurological, neuropsychological and neuropsychiatric symptoms are being reported in COVID-19 patients. Neurologists and psychiatrist, in turn, may increasingly find themselves involved in caring for patients with the novel virus.

Sars-CoV-2 usually enter the body via the enzyme angiotensin converting enzyme 2 (ACE2) in alveolar cells in the lungs. However, ACE2 is expressed in a number of other tissues and cells, such as mucous membranes of the eyes, nose and oral cavity, neurons, glia cells and endothelial cells, including those in the brain, making it a potential target of the virus.

There are several possible mechanisms for nervous system affection in COVID-19. Firstly, transneuronal transport of viruses through the olfactory nerve to the brain can induce direct injury. Sars-CoV-2 has been detected in cerebrospinal fluid in patients with encephalitis and meningitis. A second type of injury may result from an excessive immune response in the form of a "cytokine storm". Cytokines can cross the blood-brain barrier and are associated with acute necrotizing encephalopathy. A third mechanism of nervous tissue damage results from unintended host immune response effects after an acute infection. Examples of this type of indirect CNS injury are Guillain-Barré syndrome (GBS) and brain and spine demyelination. A fourth mechanism is an indirect viral injury that results from the effects of systemic illness, hypoxia and in some cases hypercoagulability, a prominent feature of severe COVID-19. Most cases of COVID-19-related neurologic complications appear to fall into this category. Severely ill patients in the intensive care unit may develop neurologic symptoms such as encephalopathy, critical illness myopathy, and neuropathy. This is common in both COVID-19 and in other diseases.

There have been several reports of nervous system manifestations in COVID-19. In a retrospective study from Wuhan China with 214 consecutive hospitalized patients, 1/3 had neurologic manifestations and nearly one half of those with severe infection. Common central nervous system (CNS) symptoms were dizziness, headache, and impaired consciousness or symptoms of acute cerebrovascular disease. The most common peripheral nervous system (PNS) symptoms included impaired taste, smell, or vision, and nerve pain. Skeletal muscular injury symptoms were also frequently reported. COVID-19 patients with CNS symptoms had lower lymphocyte levels and platelet counts and higher blood urea nitrogen levels compared to their counterparts without CNS symptoms. This may be indicative of immunosuppression in patients with COVID-19 and CNS symptoms or it may be manifestations coexisting in the same patient. Systematic brain imaging and measurements of neuron- or brain-specific biomarkers may increase the knowledge regarding nervous system manifestations in COVID-19 but were not performed in this study. Case report series with types of CNS or PNS manifestations, such as ischemic or hemorrhagic stroke, Guillain Barré syndrome, encephalitis, meningitis and toxic hemorrhagic necrotizing encephalopathy have been described. Furthermore, post infection surveillance will be necessary to identify possible post-COVID neurologic syndromes.

Moreover, COVID-19 is a significant psychological stressor, which may in addition to the neurological manifestations contribute to neuropsychiatric and neuropsychological sequela. Past respiratory viral pandemics have been associated with neuropsychiatric symptoms that may arise acutely or after variable periods of time. The long-term effect on neuropsychological functioning and the prevalence of neuropsychiatric symptoms due to COVID-19 are currently unknown. However, patients with COVID-19 are at risk of developing delirium that may cause long term cognitive impairment. Furthermore, Sars-CoV-2 proteins have been shown to interact with human proteins in multiple aging-related processes and CNS symptoms in patients with COVID-19 may put them at risk of neurocognitive complications. Given the global burden of COVID-19, long term neurocognitive complications are of importance to recognize.

Previously anxiety, depression and trauma related symptoms have been associated with CoV outbreaks. In survivors of SARS-CoV-1 active psychiatric illnesses were diagnosed in more than 40%, (PTSD (54%), depression (39%), somatoform pain disorders (36%), panic disorder (32%) and OCD (15%)) post-infection compared to pre-infection prevalence of less than 3%, and more than 27% had fatigue symptoms. Moreover, antibodies against CoV have been found in both psychoses and affective disorders. However, it is not known to which extent neuropsychological and psychiatric symptoms and disorders after COVID-19 are related to the psychological stressor or to CNS sequela after Covid-19 or to both.

Our hypotheses in this project are:

1. Nervous system manifestations and neurological sequelae are common after COVID 19.

2. Biomarkers in blood can be used to assess neurological manifestations and sequelae in COVID-19 patients at 6- and 12-months follow-up.

3. Severe COVID-19 infection predicts neurological manifestations and sequelae at 6- and 12-months follow-up.

4. Psychiatric disorders, especially anxiety and depressive disorders, but also psychotic and somatoform disorders are common after COVID-19, either due to CNS sequelae or manifestation or to perceived distress/strain.

5. Neuropsychological sequelae are common after COVID-19 either due to CNS sequelae or manifestation or to perceived distress/strain.

6. Biomarkers and imaging findings can be used to predict neuropsychiatric manifestations after Covid-19 at 6- and 12- months follow up.

7. Biomarkers in blood and imaging findings can be used to predict neuropsychological manifestations after Covid-19 at 6- and 12- months follow up.

8. Severe COVID-19 infection predicts neuropsychiatric and psychiatric disorders at 6- and 12-months follow-up.

9. Severe COVID-19 infection predicts neuropsychological sequelae at 6- and 12-months follow-up.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Sub cohort 1:

Inclusion Criteria:

• Consenting adults (age =18 years) hospitalized with definite COVID-19 included in the WHO: The NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS CoV-2 infected patients and willingness to participate in the NeuroCOVID study.

Exclusion Criteria:

• If still alive, no willingness and ability to participate in all follow-up examinations.

Sub cohort 2:

Inclusion Criteria:

• Consenting adults (age =18 years) with COVID-19 and new neurological, neuropsychological or neuropsychiatric symptoms and/or signs or participants from other COVID-19 studies than the NOR Solidary Study.

Exclusion Criteria:

• If still alive, no willingness and ability to participate in all follow-up examinations.

All participants in both sub cohorts will after the visit by neurologists be assessed by neuropsychologists and psychiatrist at 6- and 12-month follow-up if the following criteria are fulfilled:

1. Sufficient Norwegian or English speaking in order to fulfill the tests.

2. MoCA score > 18.

3. Hospital has C-L psychiatrist/neuropsychologists that participate in the study or collaborate with C-L psychiatrist/psychiatrist/clinical psychologists at nearby hospitals.

Related Conditions & MeSH terms

• Covid19

Intervention

Other:
• Observation
The study is a multi-center Norwegian prospective observational clinical study of the occurence of neurological, neuropsychological and psychiatric manifestations and sequelae in patients with COVID-19 at 6- and 12-months follow-up.

Locations

Country	Name	City	State
Norway	Sørlandet Hospital Trust	Arendal
Norway	Haukeland University Hospital	Bergen
Norway	Nordlandssykehuset	Bodo
Norway	Vestre Viken Hospital Trust Drammen	Drammen
Norway	Østfold Hospital Trust Kalnes	Grålum
Norway	Sørlandet Hospital Trust, Kristiansand	Kristiansand
Norway	Innlandet Hospital Trust	Lillehammer
Norway	Akershus University Hospital	Lørenskog
Norway	Møre og Romsdal Hospital Trust	Molde
Norway	Oslo University Hospital	Oslo
Norway	Ostfold Hospital Trust	Sarpsborg
Norway	Skien Hospital	Skien
Norway	Stavanger University Hospital	Stavanger
Norway	University Hospital of North Norway	Tromsø
Norway	St. Olav Hospital	Trondheim

Sponsors (14)

Lead Sponsor	Collaborator
Oslo University Hospital	Haukeland University Hospital, Helse Stavanger HF, Møre og Romsdal Hospital Trust, Nordlandssykehuset HF, Ostfold Hospital Trust, Sorlandet Hospital HF, St. Olavs Hospital, Sykehuset Innlandet HF, Sykehuset Telemark, The Hospital of Vestfold, University Hospital of North Norway, University Hospital, Akershus, Vestre Viken Hospital Trust

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of peripheral and central nervous affection	Rate of neurological manifestations of COVID-19	6 months
Primary	Rate of peripheral and central nervous affection	Rate of neurological manifestations of COVID-19	12 months
Primary	Rate of psychiatric disorders at 6-months follow-up	Rate of psychiatric disorders as manifestations of COVID-19	6 months
Primary	Rate of psychiatric disorders at 12-months follow-up	Rate of psychiatric disorders as manifestations of COVID-19	12 months
Primary	Neuropsychological function at 6-months follow up	Neuropsychological function at 6-months follow up months after COVID-19. MoCA with score > 18 are eligible to further testing. Neuropsychological testing cover the most important domains of cognitive function enabling valid test data across different functional domains	6 months
Primary	Neuropsychological function at 12-months follow up and change in function from 6 to 12 months.	Neuropsychological function at 12-months follow up months after COVID-19. When MoCA > 18 at 6 months, MoCA is not done at 12 months. Neuropsychological testing cover the most important domains of cognitive function enabling valid test data across different functional domains.	12 months
Secondary	Rate of stroke at 6-months follow up	Rate of stroke	6 months
Secondary	Rate of stroke at 12-months follow up	Rate of stroke	12 months
Secondary	Rate of death at 6-months follow-up	Rate of death	6 months
Secondary	Rate of death at 12-months follow-up	Rate of death	12 months
Secondary	Rate of peripheral nervous affection assessed by clinical neurological examination and/or EMG/neurography at 6-months follow-up	Rate of peripheral nervous affection assessed by clinical neurological examination and/or EMG/neurography	6 months
Secondary	Rate of peripheral nervous affection assessed by clinical neurological examination and/or EMG/neurography at 12-months follow-up	Rate of peripheral nervous affection assessed by clinical neurological examination and/or EMG/neurography	12 months
Secondary	Rate of myopathy at 6-months follow-up	Rate of myopathy	6 months
Secondary	Rate of myopathy at 12-months follow-up	Rate of myopathy	12 months
Secondary	Rate of brain MRI pathology at 6-months follow-up	Rate of brain MRI pathology	6 months
Secondary	Rate of brain MRI pathology at 12-months follow-up	Rate of brain MRI pathology	12 months
Secondary	Levels of serum neurofilaments at 6-months follow-up	Levels of serum eurofilaments	6 months
Secondary	Levels of serum neurofilaments at 12-months follow-up	Levels of serum neurofilaments	12 months
Secondary	Rate of post-COVID neurological, cognitive or neuropsychiatric manifestations in the treatment arms at 6-months follow-up	Rate of post-COVID neurological, cognitive or neuropsychiatric manifestations in the treatment arms	6 months
Secondary	Rate of post-COVID neurological, cognitive or neuropsychiatric manifestations in the treatment arms at 12-months follow-up	Rate of post-COVID neurological, cognitive or neuropsychiatric manifestations in the treatment arms	12 months
Secondary	Duration of hospital and rehabilitation stay	Duration of hospital and rehabilitation stay at 6-months follow up	6 months
Secondary	Duration of hospital and rehabilitation stay	Duration of hospital and rehabilitation stay at 12-months follow up	12 months